Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lindane-containing lice treatments will undergo relabeling to warn of overuse, discuss alternatives.

Executive Summary

LINDANE PRODUCT LABELS WILL BE REVISED TO RECOMMEND SECOND-LINE USE ONLY in the treatment of lice. FDA is recommending lindane (gamma benzene hexachloride) use only for patients who have failed to respond to, or are intolerant of, other approved lice and scabies therapies that do not contain lindane. The FDA-prompted changes are in response to claims that lindane, an insecticide used in prescription-only pediculicides, might cause neurological damage in children.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel